Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops
European Journal of Clinical Investigation · 2024
DOI: 10.1111/eci.14184 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Sarah L Miller und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Conflict of Interest, Medical Oncology, Drug Industry, Hematology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Arnold Ventures.
Abstract (Originalsprache)
Objective
To assess the characteristics and financial conflicts of interest of presenters, panellists and moderators at haematology and oncology workshops held jointly with or hosted by the US FDA.
Setting
We included information on all publicly available haematology or oncology FDA workshop agendas held between 1 January 2018 and 31 December 2022. Exposure General and research payments reported on Open Payments, industry funding to patient advocacy organizations reported on their webpages or 990 tax forms and employment in both pharmaceutical and regulatory settings.
Results
Among physicians eligible for payments, 78% received at least one payment from the industry between 2017 and 2021. The mean general payment amount was $82,170 for all years ($16,434 per year) and the median was $14,906 for all years ($2981 per year). Sixty‐nine per cent of patient advocacy speakers were representing organizations that received financial support from the pharmaceutical industry. Among those representing regulatory agencies or pharmaceutical companies, 16% had worked in both settings during their careers. Conclusions and Relevance Our findings in this cross‐sectional study show a majority of US‐based physician presenters at haematology and oncology workshops held jointly with members of the US FDA have some financial conflict of interest with the pharmaceutical industry. These findings support the need for clear disclosures and suggest that a more balanced selection of presenters with fewer conflicts may help to limit bias in discussions between multiple stakeholders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Alyson Haslam, Vinay Prasad
Förderung
- Arnold Ventures
Zitieren
APA
Miller, S. L., Haslam, A., & Prasad, V. (2024). Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14184
Vancouver
Miller SL, Haslam A, Prasad V. Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14184
BibTeX
@article{Miller2024,
author = {Miller, Sarah L and Haslam, Alyson and Prasad, Vinay},
title = {Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops},
journal = {European Journal of Clinical Investigation},
year = {2024},
doi = {10.1111/eci.14184}
}
EUVIMED